Threshold Pharmaceuticals - Worst Pharma Stocks of 2007

Company: Threshold Pharmaceuticals
Starting stock price: $3.41
Ending stock price: $0.53
Percent Change: -84.46%

Details: Threshold had a tough time of it in 2006, and the situation didn't improve in 2007 when the company halted a Phase II trial of glufosfamide for small cell lung cancer after it found that patients weren't responding to the drug. Just two weeks later Threshold chopped its 44-person workforce down to 32, concentrating on its hypoxia-activated prodrug program and the ongoing clinical trials of glufosfamide for pancreatic cancer and Phase II for ovarian cancer. Earlier this year the company said the pancreatic cancer trial would continue, but the ovarian cancer trial has been abandon due to lack of efficacy.

More News:
Threshold slashes staff in effort to cut burn rate. Report
Threshold halts lung cancer study. Report
Threshold delays release of glufosfamide analysis. Report
Threshold slashes staff in wake of quarterly loss. Report
Threshold shares drop after Phase III suspension. Report

Threshold Pharmaceuticals - Worst Pharma Stocks of 2007

Suggested Articles

Johnson & Johnson and Bayer’s Xarelto is working to reverse a sales slide, and a new indication could help.

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

To get its $12 billion opioid deal off the ground, Purdue Pharma pushed for a stay on thousands of lawsuits against it. Last week, a judge signed off.